-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, the traditional Chinese medicine industry has been frequently supported by favorable policies, and the research and development of new Chinese medicine class 1 drugs has accelerated
.
According to the new version of Minet.
com's database, up to now, 8 new Chinese medicines of Category 1 have been listed, namely the anti-tumor drug icariin soft capsule, which was approved on January 10, 2022, and the stomach drug Qirui, which was approved in the second half of 2021.
Weishu Capsules, Antidepressants Suxia Jieyu Chufan Capsules, Antigout Medicine Huzhen Qingfeng Capsules, Gynecological Medicine Kunxinning Granules, Chinese Medicine Xuanqijiangu Tablets for Detumescence and Pain Relief, Qihuang Capsules for Diabetes Medicine, Yinqiao Qingre Tablets for Cold Medicines etc.
The companies involved include Jianmin Pharmaceutical, Yiling Pharmaceutical, Yili Pharmaceutical, Tasly, Kangyuan Pharmaceutical, Fangsheng Pharmaceutical,
etc.
In addition to the 8 products already on the market, according to the China Drug Clinical Trials Publicity Database on Minet.
com, there are 60 new Chinese medicines of Category 1 that are in the stages of clinical application, clinical approval, and application for marketing, including Taizi Shenyue Capsule, Brain Traumale, etc.
Raw granules, total flavonoids capsules of Guangjincao, children's Lianhuaqinggan granules, ginkgolide dropping pills,
etc.
Among them, the antidepressant Taizishenyue Capsules, Naoshanglesheng Granules for the treatment of craniocerebral trauma, and Guangjincao Total Flavonoids Capsules for the treatment of ureteral calculi are the three products that have made rapid progress in research and development.
in the trial stage
.
It is reported that Prince Shenyue Capsule was developed by Huachun Bio/Sinopharmaceutical Dezhong.
This new type 1 traditional Chinese medicine is classified according to the registration and classification of new drug type 1.
1.
, The effect of nourishing the heart and spleen, the indications are mild to moderate depression (insufficiency of qi and yin, deficiency of both heart and spleen)
.
The Naoshang Lesheng Granules developed by Sasong Industry/Tianfang Pharmaceutical are also classified according to the new drug category 1.
1 registration.
This product has the functions of nourishing qi and nourishing blood, nourishing the brain and opening the orifices, removing blood stasis and dredging collaterals.
It is mainly used for the treatment of craniocerebral trauma and craniocerebral trauma.
After the operation, the qi and blood are weak, the cerebral artery is damaged, and the stasis meridian type paralysis
.
In addition, the total flavonoids capsules of Renfu Biotechnology are classified according to the new drug category 1.
2 registration.
This product is developed from the single-flavor Chinese herbal medicine "Guangjincao" using macroporous adsorption resin purification technology.
It is mainly used for the prevention and treatment of urine Road stones
.
Judging from the main indications of the 60 new class 1 Chinese medicines, they include both gastrointestinal diseases, colds, cardiovascular and cerebrovascular diseases, tumors and other chronic and common diseases, as well as depression and other fields
.
Depression is a common depressive disorder characterized by high incidence, high recurrence, and high disability
.
Relevant data show that the number of people with depression in China has exceeded 54 million
.
Drug therapy is the main means of treating depression
.
According to data, the domestic antidepressant market has exceeded 10 billion yuan in 2020, and it is expected that by 2022, the domestic antidepressant market will reach 18.
4 billion yuan
.
Facing the growing antidepressant market, a large number of domestic pharmaceutical companies are actively deploying in this field, including Huahai Pharmaceutical, Kelun Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Tasly, Fosun Pharma, Qianyuan Pharmaceutical, Jianfeng Group, Huahai Pharmaceutical, Hengrui Pharmaceutical, Enhua Pharmaceutical, Taiji Group, Renfu Medicine, Puluo Medicine,
etc.
Judging from the new class 1 traditional Chinese medicine drugs under development, the indications include antidepressant drugs, in addition to Taizishenyue Capsules, also include Chaijin Jieyu Anshen Tablets, which have been approved for clinical use and are indicated for depression (liver depression and spleen deficiency type)
.
With the approval of more new antidepressant Chinese medicines, it is expected to bring more treatment options to domestic depression patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to the new version of Minet.
com's database, up to now, 8 new Chinese medicines of Category 1 have been listed, namely the anti-tumor drug icariin soft capsule, which was approved on January 10, 2022, and the stomach drug Qirui, which was approved in the second half of 2021.
Weishu Capsules, Antidepressants Suxia Jieyu Chufan Capsules, Antigout Medicine Huzhen Qingfeng Capsules, Gynecological Medicine Kunxinning Granules, Chinese Medicine Xuanqijiangu Tablets for Detumescence and Pain Relief, Qihuang Capsules for Diabetes Medicine, Yinqiao Qingre Tablets for Cold Medicines etc.
The companies involved include Jianmin Pharmaceutical, Yiling Pharmaceutical, Yili Pharmaceutical, Tasly, Kangyuan Pharmaceutical, Fangsheng Pharmaceutical,
etc.
In addition to the 8 products already on the market, according to the China Drug Clinical Trials Publicity Database on Minet.
com, there are 60 new Chinese medicines of Category 1 that are in the stages of clinical application, clinical approval, and application for marketing, including Taizi Shenyue Capsule, Brain Traumale, etc.
Raw granules, total flavonoids capsules of Guangjincao, children's Lianhuaqinggan granules, ginkgolide dropping pills,
etc.
Among them, the antidepressant Taizishenyue Capsules, Naoshanglesheng Granules for the treatment of craniocerebral trauma, and Guangjincao Total Flavonoids Capsules for the treatment of ureteral calculi are the three products that have made rapid progress in research and development.
in the trial stage
.
It is reported that Prince Shenyue Capsule was developed by Huachun Bio/Sinopharmaceutical Dezhong.
This new type 1 traditional Chinese medicine is classified according to the registration and classification of new drug type 1.
1.
, The effect of nourishing the heart and spleen, the indications are mild to moderate depression (insufficiency of qi and yin, deficiency of both heart and spleen)
.
The Naoshang Lesheng Granules developed by Sasong Industry/Tianfang Pharmaceutical are also classified according to the new drug category 1.
1 registration.
This product has the functions of nourishing qi and nourishing blood, nourishing the brain and opening the orifices, removing blood stasis and dredging collaterals.
It is mainly used for the treatment of craniocerebral trauma and craniocerebral trauma.
After the operation, the qi and blood are weak, the cerebral artery is damaged, and the stasis meridian type paralysis
.
In addition, the total flavonoids capsules of Renfu Biotechnology are classified according to the new drug category 1.
2 registration.
This product is developed from the single-flavor Chinese herbal medicine "Guangjincao" using macroporous adsorption resin purification technology.
It is mainly used for the prevention and treatment of urine Road stones
.
Judging from the main indications of the 60 new class 1 Chinese medicines, they include both gastrointestinal diseases, colds, cardiovascular and cerebrovascular diseases, tumors and other chronic and common diseases, as well as depression and other fields
.
Depression is a common depressive disorder characterized by high incidence, high recurrence, and high disability
.
Relevant data show that the number of people with depression in China has exceeded 54 million
.
Drug therapy is the main means of treating depression
.
According to data, the domestic antidepressant market has exceeded 10 billion yuan in 2020, and it is expected that by 2022, the domestic antidepressant market will reach 18.
4 billion yuan
.
Facing the growing antidepressant market, a large number of domestic pharmaceutical companies are actively deploying in this field, including Huahai Pharmaceutical, Kelun Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Tasly, Fosun Pharma, Qianyuan Pharmaceutical, Jianfeng Group, Huahai Pharmaceutical, Hengrui Pharmaceutical, Enhua Pharmaceutical, Taiji Group, Renfu Medicine, Puluo Medicine,
etc.
Judging from the new class 1 traditional Chinese medicine drugs under development, the indications include antidepressant drugs, in addition to Taizishenyue Capsules, also include Chaijin Jieyu Anshen Tablets, which have been approved for clinical use and are indicated for depression (liver depression and spleen deficiency type)
.
With the approval of more new antidepressant Chinese medicines, it is expected to bring more treatment options to domestic depression patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
